Bio-Rad Laboratories (BIO) Short term Debt (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Short term Debt for 18 consecutive years, with $400.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt rose 30723.08% year-over-year to $400.7 million in Q2 2026; TTM through Jun 2026 was $400.7 million, a 30723.08% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 8.33% from the prior year.
• Short term Debt was $400.7 million for Q2 2026 at Bio-Rad Laboratories, roughly flat from $400.5 million in the prior quarter.
• Over five years, Short term Debt peaked at $400.7 million in Q2 2026 and troughed at $448000.0 in Q3 2022.
• A 5-year average of $45.2 million and a median of $511500.0 in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt tumbled 74.24% in 2022 and soared 33275.0% in 2026, its largest moves.
• Over 5 years, Short term Debt stood at $465000.0 in 2022, then increased by 7.53% to $500000.0 in 2023, then surged by 140.0% to $1.2 million in 2024, then gained by 8.33% to $1.3 million in 2025, then soared by 30723.08% to $400.7 million in 2026.
• The last three Short term Debt figures came in at $400.7 million (Q2 2026), $400.5 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.